1 April 2018 in Best Practice & Research Clinical Endocrinology & Metabolism
The melanocortin receptors (MCRs) and their accessory proteins (MRAPs) are involved in regulation of a diverse range of endocrine pathways. Genetic variants of these components result in phenotypic variation and disease. The MC1R is expressed in skin and variants in the MC1R gene are associated with ginger hair color. The MC2R mediates the action of ACTH in the adrenal gland to stimulate glucocorticoid production and MC2R mutations result in familial glucocorticoid deficiency (FGD). MC3R and MC4R are involved in metabolic regulation and their gene variants are associated with severe pediatric obesity, whereas the function of MC5R remains to be fully elucidated. MRAPs have been shown to modulate the function of MCRs and genetic variants in MRAPs are associated with diseases including FGD type 2 and potentially early onset obesity. This review provides an insight into recent advances in MCRs and MRAPs physiology, focusing on the disorders associated with their dysfunction.
19 August 2021 in Molecular Therapy Nucleic Acids
JSJacqueline van der Spuy
+2
Autosomal dominant optic atrophy (DOA) is the most common inherited optic neuropathy in the United Kingdom. DOA has an insidious onset in early childhood, typically presenting with bilateral, central visual loss caused by the preferential loss of retinal ganglion cells. 60%–70% of genetically confirmed DOA cases are associated with variants in OPA1, a ubiquitously expressed GTPase that regulates mitochondrial homeostasis through coordination of inner membrane fusion, maintenance of cristae structure, and regulation of bioenergetic output. Whether genetic correction of OPA1 pathogenic variants can alleviate disease-associated phenotypes remains unknown. Here, we demonstrate generation of patient-derived OPA1 c.1334G>A: p.R445H mutant induced pluripotent stem cells (iPSCs), followed by correction of OPA1 through CRISPR-Cas9-guided homology-directed repair (HDR) and evaluate the effect of OPA1 correction on mitochondrial homeostasis. CRISPR-Cas9 gene editing demonstrated an efficient method of OPA1 correction, with successful gene correction in 57% of isolated iPSCs. Correction of OPA1 restored mitochondrial homeostasis, re-establishing the mitochondrial network and basal respiration and ATP production levels. In addition, correction of OPA1 re-established the levels of wild-type (WT) mitochondrial DNA (mtDNA) and reduced susceptibility to apoptotic stimuli. These data demonstrate that nuclear gene correction can restore mitochondrial homeostasis and improve mtDNA integrity in DOA patient-derived cells carrying an OPA1 variant.
14 October 2014 in Endocrine Abstracts
Aberrant pseudoexon inclusion is rarely recognised as a cause of human disease. Here we report two novel, compound heterozygous mutations in nicotinamide nucleotide transhydrogenase (NNT), one of which activates a pseudoexon, as the cause of familial glucocorticoid deficiency in two siblings. Whole-exome sequencing identified a single novel, heterozygous variant (R71X) in both affected individuals. Follow-up cDNA analysis identified the pseudoexon inclusion (p.P998_D999ins23) and Sanger sequencing of genomic DNA identified a 4 bp duplication responsible for its activation. The variants segregated with the disease, R71X was inherited from the mother, P998_D999ins23 from the father and an unaffected sibling had inherited only the R71X variant. Neither variant has been annotated in any SNP or mutation databases and both will lead to premature truncation and presumably an inactive protein. The mutation resulting in pseudoexon inclusion could provide a potential target for antisense oligonucleotide therapy. Detection of such events in disease is hampered since introns, because of their frequently large size, are often excluded from mutational analyses, and it is often impossible/impractical to perform cDNA analysis.
14 October 2014 in Endocrine Abstracts
Recently, rare loss-of-function mutations of melanocortin-2-receptor accessory protein 2 (MRAP2) have been associated with severe, early-onset obesity in humans. In addition, whole body deletion and targeted brain specific deletion of the Mrap2 gene resulted in severe obesity in mice. In vitro data have shown Mrap2 interaction with the melanocortin-4-receptor (MC4R) affecting receptor signalling as a consequence. However, the mechanism by which Mrap2 regulates body weight in vivo is less well understood with differences between Mrap2 and Mc4r knockout (KO) mice phenotypes. In this study we show that Mrap2 complete KO mice, derived from an independent line and on two separate genetic backgrounds, have severe early obesity without detectable changes to food intake or energy expenditure. Hence, replicating recently published data. To further investigate the in vivo role of Mrap2 as a Mc4r accessory protein we used a plasma membrane enrichment technique to demonstrate a reduction of hypothalamic Mc4r protein surface expression in Mrap2 KO mice compared with WT littermates. Taken together, this work corroborates the role of Mrap2 in obesity and confirms that, at least in part, this is due to defective central melanocortin trafficking.